醫思健康(02138.HK)預計年度整體銷售額不少於38億港元 同比增長不少於24%
格隆匯4月28日丨醫思健康(02138.HK)公佈,截至2023年3月31日止年度,集團預期錄得整體銷售額不少於38億港元,較去年同期升幅不少於24%;集團所提供醫療服務銷售額較去年同期升幅不少於39%;集團香港及澳門美學醫療、美容及養生服務銷售額較去年同期升幅不少於4%;集團中國內地美學醫療、美容及養生服務銷售額較去年同期跌幅不多於25%;及集團其他服務銷售額較去年同期升幅不少於36%。
董事會認為美學醫療、美容及養生服務銷售額下跌主要由於(i)中國內地疫情反覆;(ii)政府實施嚴格的疫情管控措施;及(iii)中國內地多地推行社交距離限制。
香港與中國內地自2023年1月8日起推行首階段通關,並於2023年2月6日起推行全面通關。根據香港政府公開數據,於2023年1月至3月,來自中國內地的跨境旅客數量分別約為30萬、110萬及200萬人次。受益於跨境旅客人數的逐步恢復,2023年1月至3月,集團錄得內地跨境醫療旅客貢獻銷售約8,200萬港元。集團預期內地旅客的逐步恢復將對集團的業務表現產生正面影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.